Alkem Laboratories Limited Bombay S.E.

Equities

ALKEM

INE540L01014

Pharmaceuticals

Delayed Bombay S.E. 02:13:10 2024-04-19 am EDT 5-day change 1st Jan Change
4,604 INR -0.95% Intraday chart for Alkem Laboratories Limited -2.89% -11.49%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Alkem Laboratories Forms Subsidiary for Medical Devices Business MT
Alkem Laboratories Limited Announces Incorporation of Subsidiary Alkem Medtech Private Limited CI
Alkem Laboratories Gets 10 Observations from US FDA After Baddi, India Unit Inspection MT
Norway's Biosergen Secures Indian Regulatory Approval for Clinical Trial of Fungal Infections Therapy MT
Jefferies Adjusts Alkem Laboratories’ Price Target to INR4,470 From INR3,960, Keeps at Underperform MT
Transcript : Alkem Laboratories Limited, Q3 2024 Earnings Call, Feb 09, 2024
Alkem Laboratories Limited Approves Interim Dividend for Financial Year 2023-24 , Payable on 1 March, 2024 CI
Alkem Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Indian Equities Close Higher on Friday, Lifted by IT Stocks MT
Alkem Laboratories Names Successor to Outgoing CFO MT
Alkem Laboratories Limited Announces CFO Changes CI
Heritage Global, Investors Acquire Pharmaceutical Plant from Alkem Laboratories MT
Federal Machinery & Equipment Co., Heritage Global Partners, Inc., New Mill Capital LLC, Keith Machinery Corp acquired Pharmaceutical Site in Fenton Missouri from Alkem Laboratories Limited. CI
Alkem Laboratories Limited Appoints Ashish Sehgal to Hold Senior Management Position in the Company Effective 15 December 2023 CI
Alkem Laboratories Limited Submits Clinical Trial Application to Central Drugs Standard Control Organization in India CI
Alkem Laboratories Limited Submits Clinical Trial Application for First Patient Study with Bsg005 in Invasive Fungal Infections in India as A Rescue Therapy CI
Biosergen's Indian Partner Seeks Approval for Clinical Trial of Antifungal Drug Candidate MT
Alkem Laboratories Limited Appoints Kaustav Banerjee to Hold Senior Management Position CI
Alkem Laboratories Gets Three Observations from US FDA After Mandva, India Unit Inspection MT
Alkem Laboratories Appoints Sanchit Bansal to Senior Management Position CI
Alkem Laboratories Limited Appoints Madhurima Singh, Executive Director CI
Nomura Upgrades Alkem Laboratories to Buy From Neutral, Adjusts Price Target to INR4,963 From INR3,632 MT
Jefferies Adjusts Alkem Laboratories’ Price Target to INR3,600 From INR3,550, Keeps at Underperform MT
Alkem Laboratories' Consolidated Profit Jumps in Fiscal Q2; Shares Climb 6% MT
Transcript : Alkem Laboratories Limited, Q2 2024 Earnings Call, Nov 07, 2023
Chart Alkem Laboratories Limited
More charts
Alkem Laboratories Limited is an India-based company, which is engaged in the pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The Company offers its products across various therapeutic areas, such as Anti Infective, Dermatology, Diabetology, Cardiology, Gastroenterology, Osteoporosis, Rheumatology, central nervous system (CNS), Oncology, Urology, Gynecology, and Vitamins, Mineral and Nutrition. Its product range includes Rx Products, Alkem Generics and OTC Product. The Company’s product portfolio includes brands, such as Clavam, Pan, Pan-D, Taxim-O, A To Z NS, Xone, Taxim, Gemcal, Pipzo and Ondem. The Company operates through a segment, Pharmaceuticals. It has approximately 21 manufacturing facilities at multiple locations in India and the United States. The Company has approximately 800 brands and operates in 40 countries.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
4,651 INR
Average target price
5,184 INR
Spread / Average Target
+11.46%
Consensus
  1. Stock Market
  2. Equities
  3. ALKEM Stock
  4. ALKEM Stock
  5. News Alkem Laboratories Limited
  6. Alkem Laboratories : Launches Ibuprofen and Famotidine Tablets in US